Drugmaker Lupin Q3 net beats forecast on generic launches
Indian drugmaker Lupin Ltd on Monday beat estimates with a 42% growth in quarterly net profit and announced the acquisition of a Netherlands-based company that provides technology to develop injectable products.Updated: Feb 03, 2014 17:14 IST
Indian drugmaker Lupin Ltd on Monday beat estimates with a 42% growth in quarterly net profit and announced the acquisition of a Netherlands-based company that provides technology to develop injectable products.
The company, India's No 2 pharmaceutical company by market value, did not provide the financial details of the acquisition of Nanomi BV, which has patented technology platforms to develop complex injectable medicines.
"We have been wanting to get into injectables for the longest time but we wanted to get into differentiated products. We really liked the Nanomi technology," managing director Nilesh Gupta told Reuters.
"It's going to be a while before we get it translated into products but we were very interested in acquiring the technology and then build off it," he said.
Lupin's net profit in the December quarter rose 42% to Rs 4.8 billion ($76.61 million) on the launch of new drugs in its key US market, including the generic version of Eli Lilly & Company's Cymbalta used for treating major depressive disorder.
Analysts had expected Lupin's December-quarter net profit to be at Rs 4.3 billion, according to Thomson Reuters data.
The company expects to maintain its current pace of launch of four to five generic drugs each quarter in the United States, which accounted for 45% of its sales in the third quarter, in the near future, Gupta said.
Shares of Lupin, which has a market value of more than $6 billion, rose as much as 4.9% after the results.